| Product Code: ETC7609337 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Overview |
3.1 Iraq Country Macro Economic Indicators |
3.2 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, 2021 & 2031F |
3.3 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market - Industry Life Cycle |
3.4 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market - Porter's Five Forces |
3.5 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.6 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume Share, By Brands, 2021 & 2031F |
4 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of diabetes in Iraq |
4.2.2 Rising awareness about the benefits of GLP-1 agonists in diabetes management |
4.2.3 Growing healthcare infrastructure and access to healthcare services in Iraq |
4.3 Market Restraints |
4.3.1 Limited availability and affordability of GLP-1 agonists in Iraq |
4.3.2 Lack of reimbursement policies for GLP-1 agonists |
4.3.3 Regulatory challenges and approval processes for new GLP-1 agonists in the Iraqi market |
5 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Trends |
6 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market, By Types |
6.1 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Drugs, 2021- 2031F |
6.1.3 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Dulaglutide, 2021- 2031F |
6.1.4 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Exenatide, 2021- 2031F |
6.1.5 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Liraglutide, 2021- 2031F |
6.1.6 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Lixisenatide, 2021- 2031F |
6.1.7 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Semaglutide, 2021- 2031F |
6.2 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market, By Brands |
6.2.1 Overview and Analysis |
6.2.2 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Byetta, 2021- 2031F |
6.2.3 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Bydureon, 2021- 2031F |
6.2.4 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Victoza, 2021- 2031F |
6.2.5 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Trulicity, 2021- 2031F |
6.2.6 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Lyxumia, 2021- 2031F |
6.2.7 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenues & Volume, By Ozempic, 2021- 2031F |
7 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Import-Export Trade Statistics |
7.1 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Export to Major Countries |
7.2 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Imports from Major Countries |
8 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Key Performance Indicators |
8.1 Number of healthcare providers prescribing GLP-1 agonists |
8.2 Percentage of diabetic patients using GLP-1 agonists as part of their treatment regimen |
8.3 Patient adherence rates to GLP-1 agonist therapy |
8.4 Number of clinical trials and research studies on GLP-1 agonists conducted in Iraq |
8.5 Adoption rates of new GLP-1 agonist products in the Iraqi market |
9 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market - Opportunity Assessment |
9.1 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.2 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Opportunity Assessment, By Brands, 2021 & 2031F |
10 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market - Competitive Landscape |
10.1 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Revenue Share, By Companies, 2024 |
10.2 Iraq Glucagon like Peptide 1 (GLP 1) Agonists Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here